Beijing oncology biotech Avistone raises $140M Series B for commercialization in China, expansion into US
Beijing-based Avistone Biotechnology has raised 1 billion yuan, about $140 million, to bankroll commercialization of its recently approved lung cancer drug in China and run …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
